^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Neuroendocrine Tumor
    Drug:carboplatin (Alkylating agent) +
    cabazitaxel (Microtubule inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Small cell/neuroendocrine prostate cancer...First-line and subsequent treatment options...Cabazitaxel/carboplatin